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Abstract
Objective Our main objective was to compare Cutibacterium acnes (C. acnes) skin colonisation in patients with mild to 
moderate acne versus healthy controls and secondly, to evaluate a Myrtacine-based cream on C. acnes total popula-
tion and antibioresistant Cutibacteria in patients with acne.
Methods In 60 acne patients (Global Acne Severity Scale, GEA grades 2–3), of mean age 20 [15–30] years and in 24 
age- and sex- matched healthy controls, forehead strips samplings were performed for microbiological analysis of come-
dones by colony forming unit (CFU) counts of global C. acnes and erythromycin (EryR) or clindamycin-resistant (ClnR) 
populations of Cutibacterium and determination of phylotypes by MALTI-TOF. Clinical evaluations of acne patients 
(GEA, lesion count, porphyrin ﬂuorescence) were performed at baseline and after 56 days of twice-daily application of a 
Myrtacine-based cream.
Results We ﬁrst showed (i) high and similar levels of C. acnes colonisation in superﬁcial pilosebaceous follicles and 
detection of EryR and ClnR strains in both acne and control groups; (ii) different repartition of phylotypes in acne patients 
versus healthy control, with a predominance of phylotype IA in acne patients and a link between phylotype IA and 
erythromycin resistance. Besides, after treatment with the Myrtacine-based cream in acne patients, there was no 
change in C. acnes total load, but a signiﬁcant decrease of EryR Cutibacteria, reduced porphyrin production by C. ac-
nes, a decrease in acne severity (GEA), associated with reduced retentional and inﬂammatory lesions.
Conclusion Cutibacterium acnes colonisation was not signiﬁcantly different in acne versus control groups. Phylotype 
IA was predominant in acne patient and in EryR C. acnes. A Myrtacine-based cream signiﬁcantly reduced the level of 
EryR Cutibacteria in vivo and improved acne lesions.
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different phylotypes of C. acnes, in addition to an impairment
of the skin microbiome equilibrium1,2 (B. Dreno et al., this
issue). Many recent studies thus focus in determining the role
of C. acnes and its different phylotypes in inflammatory acne.
As regards acne therapy, in mild to moderate acne, topical
treatments are preferred,3–5 including antibiotics targeting
Introduction
Very recently, there has been a paradigm shift in our under-
standing of the role of Cutibacterium acnes (C. acnes, formerly 
Propionibacterium acnes) in the pathophysiology of acne. 
Instead of resulting from C. acnes hyperproliferation, acne 
would rather result from the loss of balance between the
DOI: 10.1111/jdv.15042
macrolide derivatives) or zinc, or patients treated with NSAID,
corticosteroid, or antibiotics other than anti-acneic taken during
the preceding month were not included. We also excluded
patients treated with oral retinoids treatment or any hormonal
treatment for contraceptive or anti-acneic purpose initiated or
modified during the 12 preceding weeks. During treatment,
none of the aforementioned treatments was allowed.
The group of healthy controls was constituted by volun-
teers, free of facial or dorsal acne and of any facial dermato-
sis, with no history of acne nor acne treatment in the
brotherhood, who did not use any local treatment nor any
antibiotic, anti-inflammatory or anti-histaminic oral treatment
during the four preceding weeks, were age- and sex-matched
with the acne patients included in the study group.
Interventions
Three visits were performed for acne patients: at inclusion (D0),
intermediate (D28  3 days) and at the end of the study
(D56  7 days).
At baseline, microbiological sampling was performed on 24
healthy controls and 60 acne patients for microbiological analy-
sis. Besides, in the patients only, the dermatologist performed a
clinical examination of the face at D0, D28 and D56. Concomi-
tant treatments, adverse events and treatment compliance were
recorded. Finally, another microbiological sampling was realised
on acne patients at D56.
Study product
The study product was a cream (Ducray Laboratory, France)
containing Myrtus communis leaf extract. It was applied twice
daily, on the whole face, after cleaning with a hygiene product
(soothing foaming gel).
Outcomes
The main outcome was the comparison of the number of CFU
(Colony Forming Units) of C. acnes and total C. acnes (qPCR)
in healthy controls versus acne patients.
The secondary criteria were:
• The quantification of the amount of Cutibacterium spp.
CFU resistant to Erythromycin or resistant to Clindamycin
in healthy controls and acne patients;
• The determination of the C. acnes phylotypes among
C. acnes and among EryR C. acnes in healthy controls and
acne patients
• The change in total C. acnes load and in Cutibacterium spp.
resistant to Erythromycin and to Clindamycin after 56 days
of application of a Myrtacine-based cream in patients with
acne, by measuring the amount of CFU in noninvasive sam-
pling of comedones at D0 and D56
• Follicular porphyrin fluorescence quantification by imaging
analysis based on UV standardised photography11 after
56 days of application of a Myrtacine-based cream
C. acnes. However, epidemiological studies have shown a 
marked increase in the frequency of topical antibiotic resistance 
in acne subjects – from 20% in 1979 to 64% in 2000 – especially 
resistance to erythromycin and clindamycin.6,7 As reviewed by 
Dreno et al. (this issue), C. acnes resistance may be due to sev-
eral contributing mechanisms, including the formation of bio-
film,8 which can act by restricting penetration of antibiotics.7
Myrtacine (Myrtus communis extract) has been demon-
strated to be efficient on C. acnes biofilm alone or combined 
with antibiotics using in vitro models.9 Furthermore, by target-
ing the biofilm, Myrtacine is able to potentiate the bactericidal 
activity of antibiotics and reduce C. acnes counts even with 
strains resistant to erythromycin, in vitro.9
With the aim to further understand the role of C. acnes and its 
different phylotypes in acne pathogenesis, as a main objective of 
this work, we compared total C. acnes load and antibiotic-resistant 
Cutibacterium populations, as well as C. acnes phylotype reparti-
tion in the skin of acne patients with that observed in the skin of 
age- and sex-matched healthy controls. In addition, as a secondary 
objective, we determined the effect of a Myrtacine-based cream 
targeting the biofilm of C. acnes in an open exploratory evaluation 
and quantified C. acnes populations (total and antibiotic-resistant 
strains) in patients with mild to moderate acne.
Participants and methods
Study design
This study was carried out at the Dermatology Department – CHU 
Nantes (France) and at the Clinical Skin Research Center, Pierre 
Fabre, Toulouse (France), in accordance with the ethical principles 
of the declaration of Helsinki and the guidelines for Good Clinical 
Practice. The protocol was approved by the Ethics Committee 
(Comite de Protection des Personnes (CPP) Ouest IV) and the 
ANSM (French National Agency for Medicine and Health Product 
Safety). Each volunteer signed a written informed consent.
Participants
Acne patients were included by a dermatologist. They were aged 
≥15 years with mild to moderate acne (Global Acne Severity 
Scale10 (GEA) II to III), presenting at least five papules and pus-
tules on the face (not located on the nasal pyramid), and at least 
six closed and open comedones on the face, including at least 
three on the forehead. Exclusion criteria were presence of any 
cutaneous lesion affecting the face apart from ongoing acne (i.e. 
vitiligo, psoriasis and seborrhoeic dermatitis. . .), or any chronic 
or acute progressive disease, which may interfere with the study. 
Patients who applied facial topical treatments during the preced-
ing month including anti-acneic agents (retinoids, zinc, benzoyle 
peroxide), antimicrobial agents (antibiotics, antiseptic. . .), corti-
costeroids or nonsteroid anti-inflammatory drugs (NSAID) or 
patients who took systemic anti-acneic treatment during the pre-
ceding month with antibiotics (tetracycline, macrolides,
• Determination of the evolution of retentional and superfi-
cial inflammatory lesions globally with acne severity using
GEA scale10 and through the count of lesions on the face
using ECLA scale12 at baseline, after 29 and 56 days of
application of a Myrtacine-based cream
• Safety assessment: all adverse events were documented
throughout the study. Local tolerance was assessed during
visits (D28, D56) using a 4-point scale from 1 = very good
tolerance (no functional symptom or physical sign) to
4 = poor tolerance (functional symptom and/or physical
sign leading to treatment discontinuation).
Measurement of the C. acnes load by quantitative PCR
(qPCR) Bacterial DNA was extracted from 9 mL of sample with
the DNA mini kit (Qiagen, Courtabœuf, France) according to
the manufacturer’s instruction, except for the first step where
bacteria were pelleted (1452g, 4°C for 20 min) and suspended in
180 lL TET + lysozyme buffer (Tris 20 mmol/L, EDTA
2 mmol/L, Triton-X100, lysozyme 20 mg/mL, Sigma-Aldrich)
before incubation at 30 min for 37  2°C. At the end of the
procedure, DNA was eluted in 200 lL of elution buffer and
stored at 20°C before qPCR.
DNA samples were thawed before q-PCR and 10-times
diluted to reduce the inhibitors concentration. The qPCR
reaction, primers and probes were described by Miura et al.16
Q-PCR was made using the Sso advanced Universal Probes
Supermix 2X (Bio-Rad), on a MyiQTM (Bio-Rad). Standard curve
was made with calibrated genomic DNA (gDNA) from C. acnes
(CIP 53.117T). Each sample was analysed in triplicates. A posi-
tive control was made for every sample (addition of 1 lL gDNA
of C. acnes CIP 53.117T to the reaction). For each run, negative
controls (without DNA) and negative extraction control (DNA
extraction on a mock sample) were also made.
Determination of C. acnes phylotypes by MALDI-TOF (Matrix
Assisted Laser Desorption Ionisation-Time of Flight) Each of
the 10 representative clones of C. acnes (+3 resistant clones, if
existing) stored at 80°C was thawed and cultured for 72 h on
COS at 37°C. As a result, only phylotypes present in a propor-
tion over 90% were detected.
The MALDI-TOF method described by Nagy et al.17 was used
to type C. acnes colonies – as well as to confirm the identifica-
tion at the species level. Analyses were made with a Microflex LT
MALDI-TOF (Bruker) using the MTB Compass IVD software
(Bruker). Strain identification at the species level was performed
with MALDI Biotyper IVD Compass software and its database
(DB5989). Phylotypes were determined for each spot with a
MALDI Biotyper typing software prototype for C. acnes devel-
oped by Bruker.
Statistical analysis
As this was a pilot exploratory study, and in the absence of data
from the literature, there was no rational basis to determine the
number of healthy controls. The 60 patients included allowed to
use the normal distribution to describe data variability. Microbi-
ological variables were described by quantity of C. acnes load,
using the derived variable (log10 (CFU or GU/strip) of
C. acnes), and per cent of subjects. The statistical comparison
between healthy controls and acne patients at D0 in C. acnes
total load and EryR C. acnes (log CFU) was performed by Stu-
dent’s t-test, performed at a significance level of 0.05. Compar-
isons of proportions of patients were tested with the chi-square
test, also performed at a significance level of 0.05. Regarding the
analysis of product efficacy, it was performed on the FAS
Methods of measurement
Microbiological sampling Comedone sampling of the same area 
of the face (located with a tracking mask) was performed with 
Purifying Strips (Strips Purifiants, Laboratoires Diadermine, 
Henkel, Boulogne Billancourt, France) applied on the forehead of 
subjects after humidification of the skin. After 15 min, strips were 
removed and transferred into 20 mL of modified reduced RTF13 
at ambient temperature and stored for less than 48 h at room 
temperature before microbiological analysis.
Measurement of the bacterial load of Cutibacterium spp.
(resistant or not) by culture and isolates collection One millil-
itre of each sample was transferred in 9 mL of neutralising broth 
(10% Tween 80, Sigma; 2% lecithin, Acros; 2% saponin, Acros; 
0.5% sodium thiosulfate, Sigma; in chloride-peptone buffered 
solution, bioMerieux) to neutralise components from the strip 
that could inhibit bacterial growth, and serially diluted in sterile 
distilled water. One hundred lL of each dilution was spread 
onto Columbia agar supplemented with 5% sheep blood (COS, 
Biomerieux, Marcy l’Etoile, France) and on COS supplemented 
with erythromycin (2 lg/mL; Sigma-Aldrich) and COS + clin-
damycin (4 lg/mL; Sigma-Aldrich). The clinical breakpoint we 
used for clindamycin was that defined by EUCAST14 for the 
determination of bacterial resistance for anaerobic gram-positive 
bacilli. As the clinical breakpoint of Erythromycin has not been 
defined by CLSI or EUCAST, we used the clinical breakpoint 
proposed by Ishida et al. in 2008.15 Petri dishes were incubated 
at 37  2°C under anaerobic atmosphere (Genbox, bioMerieux) 
for 5 days. Morphologically different types of colonies were 
described and counted. Cutibacterium colonies identification 
(small, round, domed, opaque, white to off-white sometimes ß-
haemolytic) was assessed by Gram staining, the incapacity to 
grow aerobically, and biochemical tests (API ID32A, 
bioMerieux).
Ten representative colonies (selection based on morphotypes 
and CFU counts) from COS and three colonies from COS+ery-
thromycin and COS+clindamycin (when present) of each subject 
were also maintained in a cryoprotective solution at 80°C for 
type determination of C. acnes.
population, with quantitative variables expressed as mean and
median values, standard deviation and range and qualitative
variables as frequencies and percentages. Comparisons between
D0 and D28 or D56 were performed using the paired Student’s
t-test or the Wilcoxon signed-rank test, at a significance level of
0.05 (P < 0.0001 was considered very significant).
Results
Demographic and baseline data
Twenty-four individuals with no history of acne were included
as healthy controls (15 female, mean age 21.6 years). They were
age- and sex-matched with sixty patients affected with acne vul-
garis (85% mild acne GEA grade 2, 15% moderate acne, GEA
grade 3). Patients aged 20 years (range: 15–30 years) were
mostly female (n = 37/60). Clinical characteristics of the
patients’ population are described in Table 1.
Main objective: Comparison of C. acnes population in
healthy controls and acne patients
C. acnes load Only two species belonging to Cutibacterium
genus were recovered: C. acnes and C. granulosum. Mean CFU
(culture) and GU (qPCR) measurements (SD) of C. acnes
loads both showed a high total colonisation by the species both
in healthy controls (5.94  1.01 log (CFU/strip) and
5.62  0.76 log (GU/strip)) and in acne patients (6.33  0.19
log (CFU/strip) and 5.62  0.71 log (GU/strip)). No significant
difference between healthy and acne groups was noted in log
(CFU/strip) (P-value calculated by Student’s t-test = 0.117).
Concerning C. granulosum carriage, only three healthy controls
(12.5%) versus 14 patients with acne (23.3%) were concerned.
Resistant isolates of Cutibacterium Among the 14 acne
patients carrying C. granulosum, EryR or ClnR resistant isolates
were detected in 10 patients. Furthermore, in 5 patients,
C. granulosum was recovered only from selective agar containing
antibiotics. Considering the apparent high proportion of resis-
tant clones of C. granulosum, the evaluation of EryR and ClnR
populations was performed on Cutibacterium spp.
Resistance to erythromycin. Erythromycin-resistant strains
(EryR) of C. acnes and C. granulosum were detected in 56.7% of
acne patients at baseline (n = 34/60), and 54.1% of healthy con-
trols (n = 13/24), without significant difference in terms of bac-
terial load between the two groups (5.05  0.93 log CFU/strip
and 4.56–0.95 log CFU/strip, respectively; P = 0.115).
Resistance to clindamycin. Clindamycin-resistant C. acnes and
C. granulosum strains were also detected (3–6 log CFU/strip) in
both acne patients (10%, n = 6/60) and healthy controls
(12.5%, n = 3/24).
C. acnes phylotype populations among healthy controls and
acne patients The analysis of C. acnes phylotype repartition
was performed on a total of 1531 C. acnes isolates from healthy
controls (n = 257) and acne patients (n = 1274).
Among C. acnes isolates collected in the patient and control
groups, the repartition of C. acnes phylotypes showed a skewed
distribution associated with acne, with a 1.54-fold increase in
the proportion of phylotype IA compared with healthy samples
(40% vs 26%). On the reverse, phylotypes IB-IC were 1.46-fold
less frequent in acne samples (24% vs 35%). The proportion of
phylotype II was similar between acne and healthy subjects (25%
vs 26%). Besides, 11% (acne patients) to 13% (healthy subjects)
of the C. acnes isolates could not be associated to any phylotype,
even though the identification at the species level was assessed
by biochemical tests and by mass spectrometry and typing was
confirmed twice by mass spectrometry. Nevertheless, all these
isolates presented similar spectral characteristics and were thus
classified into the same «unknown» group. Only one isolate of
phylotype III was found in each group of subjects. Concerning
the diversity of phylotypes per patient, it was observed that, in
the control group, 70.8% of the subjects carried less than two
major phylotypes and the maximum number of phylotypes
detected per subject was four. In the acne group, only 37.3% of
patients carried less than two major phylotypes, and the maxi-
mum number of phylotypes was 6 (P = 0.019).
When considering the proportions of subjects carrying certain
phylotypes, important variations were also observed between acne
patients and healthy controls (Fig. 1a). In particular, it was
observed that phylotype IA was carried by 73.3% of acne patients
versus 50.0% of the healthy controls (P < 0.05). On the contrary,
a higher proportion of healthy controls carried the IB_IC phylo-
types (75.0%) compared with acne patients (55.0%), although the
difference was not statistically significant. Proportions of patients
carrying phylotypes II did not vary significantly between healthy
controls and acne patients (about 45%).
Table 1 Demographic and clinical characteristics at inclusion





Age (years),Mean  SD Median [Min–Max]
Whole population, N = 60 20.22 [15–30]
Dermatological examination
Presence of particular signs apart from acne No
Evaluation of facial acne severity with GEA scale
Grade 0–1 (no or almost no acne lesions) 0
Grade 2 (mild) 51
Grade 3 (moderate) 9
Grade 4–5 (Severe or very severe) 0
Figure 1 Comparison of C. acnes phylotypes in healthy and acne
patients. (A) Percentage of subjects carrying different phylotypes
among all subjects (*P < 0.05). (B) Percentage of subjects carrying
different phylotypes among subjects carrying an EryR strain
(*P < 0.05). (C) Density of phylotypes IA (NA:all, EryR:
Erythromycine resistant) (*P < 0.05).
Phylotypes in patients carrying an Erythromycin-resistant 
isolate of C. acnes To get a better idea of the phylotypes 
potentially involved in resistance in C. acnes, subpopulations of 
healthy controls and acne patients carrying an EryR strain were 
studied.
Phylotype IA was dominant among EryR strains. However, 
its occurrence differed from 62.5% in the healthy group to 
92.6% in the acne group (Fig. 1b, P < 0.05). The load of 
phylotype IA EryR isolates was also significantly inferior in 
the healthy group compared with the acne group (P < 0.05) 
while the total load of phylotype IA was similar between both 
groups (Fig. 1c).
Secondary objective: Effects of a Myrtacine-based cream 
on C. acnes populations in acne patients
Total C. acnes load before and after 56 days of treatment The 
change in viable and culturable C. acnes load in treated acne 
patients, assessed by culture counts, was not significantly differ-
ent (0.05  0.62 log CFU/strip) between D0 (6.33  0.99) 
and D56 (6.28  1.13). Those results were confirmed by qPCR 
(i.e. measuring viable as well as nonviable and unculturable 
C. acnes), with a nonsignificant change in amount of C. acnes 
(0.05  0.61 log GU/strip) between D0 (5.62  0.71) and D56 
(5.67  0.77).
Antibiotic-resistant C. acnes and C. granulosum load before 
and after 56 days of treatment After treatment, the load in 
EryR C. acnes and C. granulosum (log CFU/strip) decreased 
from 4.95  0.99 at D0 to 4.76  1.05 at D56 (Wilcoxon, 
P = 0.024). In parallel, the load in C. acnes ClnR isolates 
decreased – although not significantly – from 4.62–0.85 log 
(CFU/strip) at D0 to 4.34  0.96 log (CFU/strip) at D56.
Production of porphyrines by C. acnes after 56 days of 
treatment After treatment, reduction in porphyrines production 
by C. acnes was observed in open comedones, follicles, and 
inflammatory lesions, of 23% (Student’s test P < 0.0001) in sur-
face and 25% in the volume of fluorescence measured on the 
standardised pictures at D56 versus D0 (Student’s test P < 0.0001)
(Fig. 2).
Evolution of acne severity according to GEA scale after 29 and 
56 days of treatment At the end of treatment, 38 of 60 
subjects (63%) had experienced a highly significant 
(P < 0.0001) decrease in their severity score compared with 
inclusion, and they were already 18 (30%) at D28 
(P < 0.0001) (Fig. 3a).
Evolution of retentional and inﬂammatory acne lesions 
according to ECLA grading after 29 and 56 days of treat-
ment ECLA score significantly decreased at the intermediate
had an improvement of their ECLA score for superficial inflam-
matory lesions, including 19 with a reduction of two grades.
Safety
There was no serious adverse event during the study and among
the adverse events recorded, none was suspected to be related to
the study product. Topical tolerance was rated “very good” for
100% of the subjects.
Discussion
Using new microbiological techniques, this exploratory study
showed that the C. acnes population of forehead follicles of
patients with acne and healthy controls did not differ in terms of
C. acnes counts, confirming that acne is not associated with an
over-proliferation of C. acnes.7,16,18 There was also no difference
between acne patients and healthy controls in terms of EryR
Cutibacterium spp. Indeed, as recently shown in the literature,
acne most likely results from a variation of C. acnes phylotypes
in pilosebaceous follicles.19 Likewise, in the present study, the
phylotype repartition was significantly different between the two
groups with the overrepresentation of type IA C. acnes in fore-
head follicles from acne patients and among EryR strains. More-
over, this study suggests that a Myrtacine-based cream
significantly reduces the level of EryR strains of C. acnes in vivo,
in association with a decrease of acne lesions.
Our analysis of C. acnes phylotypes confirmed that phylotype
IA is present both in healthy controls and in acne patients,
although it predominates in the latter group (40% of all isolates
of the acne group vs. 26% of the isolates of the healthy group).
The presence of the clade IA in healthy controls and acne
patients was demonstrated in several studies,19–22 as well as its
dominance in acne patients.23–25 While analysing the dominant
phylotypes of C. acnes in 63 patients with mild to severe acne,
Paugam et al.26 also observed that phylotypes IA1 and IA2
clones were carried by 58.6% of patients with mild acne, in the
range of what was observed in the present study (73.3% of acne
patients, Fig. 1a).
In contrast, the phylotype III, which is characterised by high
pro-inflammatory potential in skin explants,27 does not seem to
be related to acne: it was found in only one acne patient and one
healthy control. The phylotype III was also observed in only one
individual in Paugam’s study focusing on severe acne.26
Regarding phylotype II isolates, we observed that 45% of sub-
jects were carriers, without any variation between healthy and
acne group, a proportion similar to that observed by Fitz-
Gibbon et al.19 in acne or healthy patients (35–49%). These
observations support the fact that phylotype II participates in
the skin microbiome but is probably not relevant in the
pathology of acne.19,28
At last, we identified a new phylotype by mass spectrometry
analysis, which does not seem to be involved in acne (no varia-
tion of proportion between the two groups, Fig. 1a). However,
Figure 2 Reduction of porphyrines production by C. acnes after
Myrtacine-based cream treatment.
Figure 3 (A) Acne severity (GEA grades) among the 60 acne
patients according to time. (B) Reduction of acne lesions
(measured by ECLA) after Myrtacine-based cream treatment
*P < 0.0001.
visit (D28) and further at the end of treatment, for both reten-
tional and superficial inflammatory lesions (P < 0.0001)
(Fig. 3b). At D56 versus D0, 37 patients (62%) showed an 
improvement of their ECLA score for retentional lesions, includ-
ing 12 with a reduction of two grades, and 52 patients (87%)
before the apparition of acne and might explain the failure of
first-line antibiotic treatments. Considering the increasing levels
of resistant bacteria and the effect of long-term antibiotics treat-
ments on the microbiota,39 this phenomenon should be investi-
gated in more details.
Furthermore, we confirmed that the phylotype IA was clearly
associated to erythromycin resistance, as a high proportion of
C. acnes EryR isolates, especially from acne individuals, were
phylotype IA strains (Fig. 1b & c), in accordance with the
studies of Lomholt and Kilian37 and of Nakase et al.36
A second part of the study demonstrated that a
Myrtacine-based cream in vivo, significantly reduced the
level of erythromycin-resistant strains of Cutibacterium and
this was associated with a decrease in acne lesions. These
data corroborate the results obtained in vitro in a previous
study using a dynamic model of biofilm formation, demon-
strating the destructuring effect of Myrtacine on a mature
C. acnes biofilm formed of both sensitive and erythromycine
and clindamycine-resistant strains.9 The formation of C. acnes
biofilm is now considered as responsible for the in vivo resis-
tance of C. acnes to the main antimicrobials prescribed in
acne vulgaris8 (B. Dreno, this issue). We can therefore
hypothesise that in vivo, as it was described in vitro,
Myrtacine may impair the formation and/or the persistence
of C. acnes biofilm in the pilosebaceous follicle, leading to an
increased sensitivity of bacterial cells to the immune system –
even though the total load of C. acnes is not modified in the
patient skin. Furthermore, as C. acnes biofilm formation
seems associated with an increased production of virulence
factors,8 its disorganisation may also lead to a loss of viru-
lence of bacterial cells, which may explain the decrease in
erythromycin-resistant strains observed after treatment with
the Myrtacine-based product. Another hypothesis, which
needs to be further explored, is that Myrtacine might have
a direct effect on the expression of virulence factors.
With the advent and progress of antibiotic resistance in all
medical fields, it is of utmost interest to develop strategies,
which directly overcome the mechanisms of bacterial resis-
tance40 and limit antibiotic use.41 Indeed, in the last decade, bac-
teria resistance to antibiotics, macrolides and tetracyclines,42,43
but also rifampicin,44 has dramatically increased, leading to a
renewed interest in nonantibiotic treatments.45 We have also
observed an improvement of acne lesions, with a 42% and 19%
reduction in the score of inflammatory and retentional lesions,
respectively, at D56. However, a limitation of this study lies in
its open design and these results would need to be reproduced in
a larger placebo-controlled study.
In conclusion, our study focused on Cutibacterium species
only, but it will be interesting to study other species forming
pilosebaceous microbiota, such as Staphylococci. Yeast popula-
tion could also be of interest, especially Malassezia noticeably
less present in acne patients than in healthy controls.46
its proportion (more than 10%) suggests that it should be more 
extensively studied.
One important feature of the present study was the phylotype 
determination of 10 clones per subject (taking into account the 
apparent representativeness), which led us to study the C. acnes 
phylotype richness per patient. To our knowledge, only two 
papers so far have described the richness of C. acnes phylotypes 
per patient. Lomholt et al.20 observed a higher number of differ-
ent phylotypes per patient in healthy subjects (4) vs. acne 
patients (2). On the contrary, Barnard et al.1 observed a wider 
“richness” in terms of C. acnes ribotypes in acne patients vs. 
healthy subjects. In the present study, more than 70% of healthy 
subjects carried two phylotypes and more than 70% of acne 
patients carried three phylotypes indicating a higher richness of 
C. acnes in acne patients compared to controls. Further analyses 
would be needed concerning the diversity of phylotypes per 
patient to clarify these contradictory results. Nevertheless, they 
are in accordance with the potential reversibility of the shift 
concerning phylotype IA dominance in acne patients.
Another originality of our study is the analysis of the charac-
teristics of resistant isolates of C. acnes. A high percentage of 
individuals (from 40% to 54.1%) carried a resistant Cutibac-
terium strain, regardless of the group to which they belonged 
(healthy or acne), indicating the high level of resistance of that 
species. In UK, a steep increase in C. acnes resistance has been 
observed from 20% in 1988 to 72% of patients in 1997 and this 
proportion has likely increased ever since.29 In a Colombian 
study in 100 patients with facial acne, C. acnes antimicrobial 
resistance was demonstrated even in isolates from patients with 
no previous history of antibiotic use.30 To our knowledge, this is 
the first study to report the level of resistance to antibiotic of 
Cutibacterium spp. in healthy controls. Interestingly, the per-
centage of subjects with EryR Cutibacterium spp. was relatively 
high in both groups (more than 54%) and did not differ signifi-
cantly in term of CFU load. The literature reports various levels 
of resistance among C. acnes strains: from 6.1% to 7.6% of EryR 
strains31 to 98% of EryR strains,32 with various intermediate 
levels.33–38 Nevertheless, it is worth mentioning that in most of 
these studies, (i) sampling was performed on the skin (with 
swabs) and did not always take into account the pilosebaceous 
gland containing C. acnes; and (ii) one Cutibacterium isolate 
(the main) per patient was isolated by culture on nonselective 
agar (without antibiotics), then its sensibility to antibiotics was 
analysed. By contrast, in our study, Cutibacterium from superfi-
cial pilosebaceous follicles were directly grown on selective agar. 
Consequently, resistant strains, that can be present in low pro-
portions, were recovered, while they could have been occulted 
by sensible strains on nonselective agar. Indeed, among the 34 
acne patients carrying an EryR strain, the EryR Cutibacterium 
spp. was subdominant (≤10% of total Cutibacterium spp.) in 30 
patients (88%; data not shown). This result suggests that resis-
tant Cutibacterium spp. might exist in pilosebaceous follicles
The next step will consist in testing if a Myrtacine-based
cream is able to re-establish a balance between C. acnes phylo-
types and potentially modify C. acnes expression virulence
factors or factors involved in biofilm formation.
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